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Adult	 male	 albino	 mice	 in	 a	 shuttle	 box	 system	 were	 used	 for	 examination	 of	 learning	
for	 avoidance	 behavior	 and	 its	 deactivation.	We	measured	 the	 step-through	 latency	 in	 the	
acquisition	of	the	task	(STLa)	before	injections	of	the	drugs	tested	(fluoxetine	and	URB597	 
(a	 serotonin	 reuptake	 inhibitor,	 SSRI,	 and	 an	 agent	 preventing	 decomposition	 of	 endo- 
cannabinoids,	 respectively)	 and	 the	 respective	 latency	 24	 h	 later	 after	 injections	 of	 these	
agents	(STLr);	total	time	spent	in	the	dark	compartment	(TDC)	was	also	measured	in	these	
situations.	In	mice	that	received	fluoxetine	(5,	10,	and	20	mg/kg),	the	STLr	were	longer	than	
those	 in	 the	control,	and	 the	difference	was	significant	at	10	mg/kg.	 Injections	of	URB597	
decreased	the	STLr	and,	at	medium	and	high	doses	(0.3	and	1.0	mg/kg),	provided	significant	
differences.	All	 doses	 of	 fluoxetine	 led	 to	 significant	 decreases	 in	 the	TDC	 values,	 while	
injections	of	URB597	increased	this	index	(at	0.3	and	1.0	mg/kg,	the	shifts	were	significant).	
Combined	 injections	 of	 fluoxetine	 and	 URB597	 (5	 +	 0.1,	 10	 +	 0.3,	 and	 20	 +	 1.0	mg/kg)	
increased	the	STLr	values	and	decreased	TDC	values	to	the	levels	comparable	with	those	at	
isolated	injections	of	fluoxetine	in	the	respective	doses.	Thus,	fluoxetine	improved	memory,	
while	URB597	impaired	it;	fluoxetine	is	capable	of	nullifying	negative	effects	of	URB597.
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INTRODUCTION
Serotonin	is	one	of	the	most	important	neurotransmitters	
involved	 in	 the	 memory	 and	 learning	 processes	 [1].	
Cannabinoids	also	play	important	roles	in	the	control	
of	 neurobehavioral	 phenomena	 [2].	 The	 relationship	
between	 cannabinoids	 and	 the	 memory	 system	 was	
examined	 in	 a	 few	 studies.	 It	 was	 reported	 that	
endocannabinoids	 (like	 anandamide)	 impair	 learned	
behavior	[3].	At	the	same	time,	another	study	showed	
improvement	 in	 cognition	 and	 memory	 under	 the	
influence	 of	 these	 agents	 [2].	 The	 serotonin	 system	
affecting	 the	 memory	 structures	 plays	 an	 important	
role	in	mood	disorders	and	dysfunction	of	serotonergic	
neurotransmission	in	various	mental	diseases	[4].	This	
is	why	serotonin	reuptake	inhibitors	(SSRIs)	are	most	
frequently	used	in	the	treatment	of	major	depression	[5].	
We	used	fluoxetine	as	one	of	the	SSRIs	in	the	current	
study.	This	agent	demonstrated	no	binding	affinity	 in	
the	brain	 for	 any	other	major	 receptor	 classes,	 and	 it	
is	characterized	by	a	relatively	long	half-life	in	the	rat	
[6].	 There	 are,	 however,	 some	 reports	 that	 serotonin	 
(5-HT)	providing	activation	of	5-HT	receptors	impaired	
short-term	 memory,	 and	 blocking	 of	 the	 respective	
effects	 may	 intensify	 the	 antidepressant	 effect	 of	
SSRIs	and	improve	cognition	[7].	It	was	reported	that	
fluoxetine	 improved	 cognition	 and	 spatial	 memory	
[5],	but	some	results	are	contradictory	[8,	9].	
Type	 1-cannabinoid	 receptors	 (CB1)	 and	 5-HT	
receptors	 are	 distributed	 in	 the	 hippocampus,	 and	
both	of	them	exert	effects	on	the	memory	and	learning	
functions.	Thus,	it	was	suggested	that	their	combined	
activation	 may	 affect	 learning	 and	 memory	 in	 a	
complex	mode	[10].	This	aspect	has	not	been	studied	
well	 until	 now.	 So,	we	 decided	 to	 study	 the	 effects	
of	combined	potentiation	of	the	effects	of	endogenous	
serotonergic and cannabinoid systems on memory in 
mice.
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Animals. Male	albino	mice	(body	mass	20-30	g)	were	
used	 in	 this	 study.	The	animals	were	housed	 five	per	
cage	and	maintained	at	20	±	2°C	and	at	a	12/12-h	light/
dark	photocycle	(lights	on	07:00	a.m.).	Water	and	food	
were	available	ad libitum.	All	mice	were	acclimatized	
to	the	environment	for	at	least	10	days	prior	to	the	start	
of	 behavioral	 testing.	 They	 were	 trained	 to	 perform	
the	step-through	inhibitory	avoidance	task	(IAT).	The	
mice	received	single	intraperitoneal	(i.p)	injections	of	
saline,	fluoxetine	(5.0,	10,	or	20	mg/kg),	URB597	(0.1,	
0.3,	or	1.0	mg/kg),	or	of	their	combination	(fluoxetine	
+	URB597,	5	+	0.1,	10	+	0.3,	or	20	+	1.0	mg/kg).	After	
this,	 their	 retention	 of	 the	memory	 performance	was	
evaluated.
Inhibitory Avoidance Apparatus. The	 apparatus	
and	 procedure	 were	 basically	 the	 same	 as	 those	 in	
our	previous	studies	[11-13].	The	apparatus	consisted	
of	 a	 lighted	 chamber	 and	 a	 dark	 one.	 Between	 two	
chambers,	there	was	a	rectangular	opening	that	could	
be	closed	by	an	opaque	guillotine	door.	The	 floor	of	
both	chambers	was	equipped	with	stainless	steel	rods,	
and	the	floor	of	the	dark	chamber	could	be	electrified.	
Mice	were	placed	 in	a	 lighted	compartment	of	 the	
apparatus	 facing	away	from	the	door;	5	sec	 later,	 the	
guillotine	 door	was	 raised.	Once	 the	mouse	 entered	
the	dark	 compartment,	 the	door	was	 closed,	 and	 the	
mouse	 was	 taken	 from	 the	 dark	 compartment	 into	
its	home	cage.	The	habituation	 trial	was	 repeated	30	
min	 later	 and	 followed	 (after	 the	 same	 interval)	 by	
the	 first	 acquisition	 trial.	 The	 entry	 latency	 to	 the	
dark	 compartment	 (step-through	 latency,	 STL)	 was	
recorded	when	 the	 animal	 had	 placed	 all	 four	 paws	
on	the	floor	of	the	dark	compartment.	After	an	animal	
spontaneously	 entered	 the	 dark	 compartment,	 the	
guillotine	 door	 was	 lowered,	 and	 a	 mild	 electrical	
shock	(0.6	mA)	was	applied	for	3	sec.	The	mouse	was	
retained	 in	 the	 apparatus	 and	 received	 a	 foot-shock	
each	time	the	animal	re-entered	the	dark	compartment.	
Training	was	 terminated	when	 the	mice	 remained	 in	
the	light	compartment	for	consecutive	120	sec.	
Experimental Procedures. The	 animals	 were	
divided	 into	 10	 groups	 (n	 =	 8	 in	 each).	 They	 were	
trained	 for	 the	 step-through	 IAT.	 The	 STL	 of	 the	
first	acquisition	 trial	and	 the	number	of	 trials	 to	 IAT	
acquisition	were	recorded.	
The	 retention	 test	 was	 performed	 24	 h	 after	 the	
IAT	 acquisition	 trial.	 The	 animals	 received	 single	
i.p	 injections	of	 the	above-mentioned	agents	30	min	
before	the	retention	test.	Then,	each	mouse	was	placed	
in	a	lighted	chamber	as	in	the	IAT	training;	5	sec	later,	
the	guillotine	door	was	raised.	Then,	the	STL	and	time	
spent	 in	 the	dark	compartment	 (TDC)	were	 recorded	
up	 to	 300	 sec.	 If	 the	 mouse	 did	 not	 enter	 the	 dark	
compartment	within	 this	 time	 interval,	 the	 retention	
test	was	terminated,	and	a	ceiling	score	of	300	sec	was	
assigned.	
Statistical Analysis.  Statistical	 significance	
of	 the	 differences	 of	 each	 measured	 parameter	
between	experimental	groups	was	estimated	by	one-
way	 ANOVA	 or	 Kruskal–Wallis	 non-parametric	
ANOVA	and	followed	by	the	Tukey	or	Dunn	tests	for	
multigroup	 comparison	when	 appropriate.	 The	 zero	
hypothesis	probabilities	below	0.05	were	considered	
significant.	All	data	presented	in	the	figures	are	given	
as	means	±	s.e.m.
RESULTS
Acquisition. There	were	neither	significant	difference	
in	 the	 number	 of	 trials	 to	 acquisition	 nor	 in	 the	STL	
in	 the	 acquisition	 of	 the	 task	 (STLa)	 between	 the	
experimental	 groups.	 There	 was	 also	 no	 difference	
in	 the	mean	 body	mass	 among	 all	 groups	 (P	 >	 0.05;	 
Fig.	1).
Retention. In	the	retention	test	done	24	h	after	the	
training	period,	the	one-way	ANOVA	test	indicated	that	
there	was	a	 significant	difference	 in	 the	STL	(STLr)	
values	between	the	experimental	groups	(Fig.	2).	The	
Tukey	 post-hoc	 test	 revealed	 that	 the	 STLr	 in	 the	
fluoxetine	(10	mg/kg)-treated	group	was	significantly	
longer	than	that	in	the	control	(P	<	0.05).	The	values	
of	STLr	 in	 the	URB597	(0.3	and	1.0	mg/kg)-injected	
groups	were	significantly	shorter	 in	comparison	with	
the	control	 (P	<	0.05	and	P	<	0.01,	 respectively).	 In	
the	 three	 (fluoxetine	+	URB597)-treated	groups,	 the	
STLr	values	were	significantly	longer	than	those	in	the	
control	(P	<	0.05).	
Statistical	 comparison	 of	 the	 TDC	 by	 one-way	
ANOVA	 indicated	 that	 there	 was	 a	 significant	
difference	between	experimental	groups	(Fig.	2).	The	
Tukey	 post-hoc	 test	 showed	 that,	 in	 the	 fluoxetine	
(5,	10,	and	20	mg/kg)-treated	groups,	 the	TDCs	were	
highly	significantly	 shorter	 than	 those	 in	 the	control	 
(P	 <	 0.01,	P	 <	 0.001,	 and	P	 <	 0.01,	 respectively).	
On	 the	 other	 hand,	 in	 the	 URB597	 (0.3	 and	 
1.0	mg/kg)	mice,	 the	TDCs	were	much	 longer	 than	
those	 in	 the	 control	 (P	 <	 0.001).	At	 the	 same	 time,	
injections	 of	 fluoxetine+URB597	 in	 all	 the	 three	
combinations	used	led	to	highly	significant	(P	<	0.001)	
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F i g. 1.	Number	of	 trials	 to	 inhibitory	avoidance	 test	 acquisition	
(A),	 step-through	 latency	 in	 acquisition	 trials,	 sec	 (B),	 and	 body	
mass	 of	 the	 mice,	 g	 (C)	 in	 all	 experimental	 groups.	 Columns	
show	means	 ±	 s.e.m.	 *P	 <	 0.05,	 **P	 <	 0.01,	 and	 ***P	 <	 0.001,	
as	 compared	with	 the	 control	 group.	 F5,	 10,	 and	 20	 are	 doses	 of	
fluoxetine,	respectively,	5,	10,	and	20	mg/kg;	U0.1,	0.3,	and	1.0	are	
doses	of	URB597,	 respectively,	0.1,	0.3,	and	1.0	mg/kg;	Contr.	 is	
the	control.
Р и с. 1. Кількість	реалізацій	при	тренуванні	в	тесті	гальмівного	
уникання	(А),	латентних	періодів	(с)	переходу	межі	в	перебігу	
тренування	(B)	та	маси	тіла	мишей	(г)	в	усіх	експериментальних	
групах	(С).
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F i g. 2.	Values	 of	 the	 step-through	 latency	 in	 the	 retention	 test,	 sec	 (A)	 and	 total	 time	 spent	 in	 the	 dark	 compartment,	 sec	 (B)	 in	 all	
experimental	groups.	Other	designations	are	the	same	as	in	Fig.	1.	
Р и c. 2. Значення	латентних	періодів	(с)	переходу	межі	у	відставленому	тесті	(А)	та	загального	часу	(с),	проведеного	в	темному	
відсіку	(B)	в	усіх	експериментальних	групах.
shortenings	of	TDCs	to	the	levels	close	to	those	in	the	
“pure”	fluoxetine-injected	groups.
DISCUSSION
Different	neurotransmitters	are	involved	in	the	memory	
and	 learning	 processes,	 and	 one	 of	 the	 important	
ones,	 from	 this	 aspect,	 is	 serotonin	 [1].	On	 the	other	
hand,	 cannabinoids	 also	 play	 important	 roles	 in	 the	
neurobehavioral	 processes	 [2].	 The	 cannabinergic	
system	components,	such	as	 its	 ligands	and	receptors	
(CB1s),	are	distributed	in	 the	hippocampus	and	other	
structures	 related	 to	 memory;	 it	 is	 well	 known	 that	
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the	 hippocampus	 is	 an	 important	 center	 for	 learning	
and	memory	formation.	Type	1-cannabinoid	receptors	
are	present	in	presynaptic	terminals	of	neurons	of	the	
hippocampus	and	striatal	complex	[14].	
Our	 study	 showed	 that	 the	 STLr	 values	 (STL	 of	
going	 to	 the	 dark	 compartment	 after	 injections	 of	
URB597	 and	 fluoxetine)	 24	 h	 after	 the	 task	 (IAT)	
acquisition	 in	 groups	 that	 received	 moderate	 (0.3	
mg/kg)	 and	 high	 doses	 (1.0	 mg/kg)	 of	 URB597	
were	 significantly	 shorter	 than	 in	 the	 control	 
(P	 <	 0.05).	 The	 TDC	 values	 altogether	 (at	 low,	 
0.1	mg/kg,	moderate,	0.3	mg/kg,	and	high	1.0	mg/kg	
doses	 of	 URB597)	 were	 greater	 than	 in	 the	 control	
group	(P	<	0.001),	 suggesting	 that	endocannabinoids	
significantly	 impair	 memory	 processing.	 There	 are	
different	 and	 controversial	 communications	 with	
respect	to	the	effects	of	cannabinoids	on	memory	and	
learning	processing.	At	the	same	time,	it	was	reported	
that	exogenous	cannabinoids	disrupt	encoding	 in	 the	
process	 of	 memorization	 by	 altering	 the	 functions	
of	 a	 specific	 type	 of	 hippocampal	 neurons	 [15],	
and	 that	 endocannabinoids	 exert	 a	 negative	 effect	
on	 the	 hippocampus-related	 encoding	 for	 short-
term	memory	 [15].	 In	our	 study,	a	negative	effect	of	
cannabinoids	 on	 memory	 is	 consistent	 with	 earlier	
reports.	Administration	 of	 a	 cannabinoid	 antagonist	
SR	 (SR14176A)	 attenuated	 the	memory	 impairment	
caused	 by	 anandamide	 and	 improved	 memory	 and	
learning	[16].	Local	administration	of	SR	(SR14176A)	
in	 the	delayed	 radial	maze	 task	caused	 the	blockade	
of	 CB1	 receptors	 and	 enhanced	 consolidation	 of	
spatial	 memory	 [17].	 Another	 study	 reported	 that	
endocannabinoids	 impaired	 memory	 and	 caused	
extinction	of	previously	trained	behavior	[3].	Studies	
on	CB1-knockout	mice	 in	 the	 objective	 recognition	
task	 showed	 that	 these	 animals	 demonstrated	 better	
memory	 than	 the	wild-type	 control;	 spatial	memory	
was	facilitated	[18].	In	other	studies,	it	was	described	
that	 administration	 of	 a	 CB1	 antagonist	 (AM251)	
provided	 the	 blockade	 of	 extinction	 of	 memory,	
improvement	of	the	performance	related	to	short-term	
memory,	 facilitation	of	memory,	and	reversion	of	 the	
cognition	deficits	caused	by	cannabinoid	agonists	[16,	
19,	20].	All	 the	above	 reports	agree	with	our	 results.	
Nonetheless,	 it	 should	 be	mentioned	 that	 we	 found	
some	 reports	 that	 are	 in	 contrast.	As	 was	 reported	
earlier,	 administration	 of	 a	 cannabinoid	 antagonist	
impaired	the	spatial	learning	function	[21],	and	a	CB1	
receptor	antagonist	negatively	 influenced	memory	 in	
certain	tests	[22].
The	 serotonergic	 system,	 by	 acting	 via	 the	
prefrontal	cortex,	dorsal	hippocampus,	and	amygdalar	
complex	[23],	plays	important	roles	in	mood	disorders.	
Dysfunction	 of	 serotonergic	 neurotransmission	
induces	 various	 mental	 disorders	 [4];	 thus,	 SSRIs	
became	the	most	frequently	used	agents	for	treatment	
of	 major	 depression	 [5].	 The	 SSRIs	 increased	 the	
amount	of	5-HT	receptors.	The	effect	of	5-HT	can	be	
explained	by	its	high	level	in	brain	structures	involved	
in	cognition	 (hippocampus	and	 temporal	cortex)	 [24,	
25].	The	5-HT	receptor	overactivation	impaired	short-
term	memory,	 and	 blocking	 of	 these	 receptors	 may	
improve	the	antidepressive	effect	of	SSRI	and	enhance	
cognition	[7].	
Our	 results	 showed	 that	 the	 STLr	 value	 after	
injections	of	URB597	and	 fluoxetine	 into	 the	animal	
group	that	received	a	moderate	dose	of	fluoxetine	(10	
mg/kg)	was	longer	than	that	in	the	control	group;	the	
analogous	 trend	 was	 observed	 in	 other	 fluoxetine-
injected	groups.	In	all	 three	groups	that	received	low	
(5	mg/kg),	 moderate	 (10	mg/kg),	 and	 high	 (20	mg/
kg)	doses	of	 fluoxetine,	 the	TDCs	were	 shorter	 than	
in	the	control	group	suggesting	an	improvement	effect	
on	 the	memory	 function	by	 fluoxetine.	Most	 studies	
reported	 comparable	 results.	 Fluoxetine	 improved	
cognition	 and	 spatial	 memory,	 and	 SSRIs	 partly	
removed	 memory	 deficits	 in	 patients	 with	 various	
pathological	 conditions	 [5,	 26].	At	 the	 same	 time,	
some	 reports	 are	 in	 contrast	with	 our	 findings	 [27].	
Fluoxetine	was	 reported	 to	 impair	different	 types	of	
memory	and	cognition	in	patients	with	various	mental	
disorders	[8,	28,	29];	so,	there	are	some	contradictions	
also	 in	 this	 field.	Therefore,	 the	mechanisms	 of	 the	
actions	of	 the	 serotonergic	 system	and	cannabinoids	
and	 their	effects	on	memory	processing	and	 learning	
remain	 incompletely	 identified.	Fluoxetine	 increased	
neurogenesis	 in	 the	 hippocampus	 and	 other	 regions	
associated	with	cognition	and	memory	[30].	
We	 found	 clear	 indications	 that	 the	 serotonergic	
system	 and	 endocannabinoid	 system	 may	 provide	
combined 	 e ffec t s . 	 Endocannabino ids 	 a ffec t	
serotonergic	 neurons	 [10].	 On	 the	 other	 hand,	 CB1	
and	5-HT	 receptors	 are	 present	 in	 the	hippocampus,	
and	 it	 seems	 that	 their	 combined	 activation	 can	
affect	memory	and	 learning	 in	a	complex	mode	[31].	
Fluoxetine	 increases	 the	 amount	 of	 CB1s	 in	 the	
hippocampus	 and,	 thus,	 can	modify	 the	 cannabinoid	
system	[32].
This	 aspect	 (combined	 action	 of	 fluoxetine	 and	
cannabinoids	on	memory)	was	not	 investigated	until	
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now.	This	in	why	we	studied	the	effects	of	both	these	
factors	 in	 the	 groups	 that	 received	 fluoxetine	 and	
URB597	 together.	Our	 results	 showed	 that	 the	STLr	
values	 in	 all	 “mixed”	 groups	 (5	mg/kg	 fluoxetine	 +	 
+	 0.1	 mg/kg	 URB597,	 10	 mg/kg	 fluoxetine	 +	 
+	 0.3	 mg/kg	 URB597,	 and	 20	 mg/kg	 fluoxetine	 +	 
+	1.0	mg/kg	URB597)	were	longer	(P	<	0.05)	than	in	
the	control	group.	At	 the	same	 time,	 the	TDCs	 in	all	
“mixed”	groups	were	shorter	than	those	in	the	control	
(P	 <	 0.001),	 suggesting	 that	 fluoxetine	 abolished	
negative	effects	of	endocannabinoids	on	memory.	
How	serotonin	affects	the	cannabinoid	system?	We	
suggest	 that	 serotonin	 can	do	 this	via	 its	 interaction	
with	 the	 dopaminergic	 and	 glutaminergic	 systems	 
[1,	33-35].	On	the	other	hand,	fluoxetine	can	increase	
the	number	of	CB1	receptors	in	the	hippocampus,	and	
the	 serotonergic	 system	can	modify	 the	 cannabinoid	
system	 [32];	 thus,	 the	 serotonergic	 and	 cannabinoid	
systems	may	 affect	 each	 other	 via	 this	 mechanism.	
Other	 reports	 may	 help	 us	 to	 understand	 the	
mechanism	 of	 such	 combined	 activation	 in	memory	
processing;	endocannabinoids	have	a	nerve-protective	
effect	 and	 promote	 neuronal	 proliferation.	 Both	 the	
above	 systems	 affect	 neuronal	 differentiation	 in	 the	
hippocampus	and	other	 structures	 related	 to	memory	
[7,	23,	36,	37].	
Our	study	showed	how	the	serotonergic	system	can	
improve	 memory;	 on	 the	 other	 hand,	 cannabinoids	
can	 impair	 memory.	 It	 can	 be	 concluded	 that	 the	
serotonergic	 system	nullifies	 the	 negative	 effects	 of	
cannabinoids	on	memory.	
Our	 study	 has	 some	 limitations.	 For	 example,	we	
did	 not	 study	 the	 effects	 of	 the	 above	 systems	 on	
neurogenesis	and	on	other	related	cerebral	phenomena.	
We	suggest,	however,	that	some	obtained	information	
may	help	one	to	identify	in	more	detail	the	mechanisms	
of	 interaction	 between	 the	 serotonergic	 system	 and	
cannabinoids	in	future	studies.	
Based	on	our	 own	 research,	we	believe	 that	 there	
is	a	need	for	further	study	to	determine	the	combined	
potential	 effect	 of	 endogenous	 serotonergic	 and	
cannabinoid	systems	on	memory.
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І	КАНАБІНОЇДНУ	СИСТЕМИ,	НА	ФОРМУВАННЯ	
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Р	е	з	ю	м	е
У	 дорослих	 білих	 мишей-самців	 досліджували	 навчання	
поведінці	 уникання	 та	 деактивацію	 цього	 процесу	 в	
системі	 із	 човниковою	 камерою.	 Виміряли	 латентні	
періоди	перетину	межі	при	навчанні	дó	ін’єкції	тестованих	
агентів	 –	 флуоксетину	 (інгібітора	 зворотного	 захоплення	
серотоніну,	SSRS)	та	URB597	(речовини,	що	перешкоджає	
декомпозиції	 ендоканабіноїдів)	 і	 після	 таких	 ін’єкцій	
(STLa	 і	STLr)	відповідно;	визначали	також	загальний	час,	
проведений	 у	 темному	 компартменті	 в	 даних	 ситуаціях	
(TDC).	 У	 мишей,	 які	 отримували	 флуоксетин	 (5,	 10	
або	 20	 мг/кг),	 STLr	 ставали	 більшими,	 ніж	 у	 контролі,	
причому	 в	 разі	 використання	 10	 мг/кг	 різниця	 	 середніх	
була	 вірогідною.	 Ін’єкції	 URB597	 зменшували	 значення	
TDC,	 і	 при	 середніх	 і	 високих	 дозах	 (0.3	 і	 1.0	 мг/кг)	
відмінності	перевищували	рівень	вірогідності.	Флуоксетин	
у	всіх	дозах	зумовлював	 істотне	зменшення	значень	TDC,	
а	 ін’єкції	 URB597	 збільшували	 цей	 показник	 (при	 0.3	
та	 1.0	 мг/кг	 зрушення	 були	 вірогідними).	 Комбіновані	
ін’єкції	 флуоксетину	 та	URB597	 (5	 +	 0.1,	 10	 +	 0.3	 і	 20	 +	 
+	 1.0	 мг/кг)	 призводили	 до	 збільшення	 значень	 STLr	
і	 зменшення	 TDC	 до	 рівнів,	 порівнянних	 із	 тими,	 які	
спостерігалися	в	умовах	 ізольованих	уведень	флуоксетину	
у	відповідних	дозах.	Таким	чином,	флуоксетин	покращував	
пам’ять,	 тоді	 як	 URB597	 порушував	 її;	 флуоксетин	 має	
здатність	нейтралізувати	негативні	ефекти	URB597.
REFERENCES
1.	 M.	 Vaswani,	 F.	 Linda,	 and	 S.	 Ramesh,	 “Role	 of	 serotonin	
reuptake	 inhibitors	 in	psychiatric	disorders:	a	comprehensive	
review,”	Neuropsychopharmacol.	Biol. Psychiat.,	27,	85-102	
(2003).
2.	 L.	Oliveira	Alvares,	B.	P.	Genro,	F.	Diehl,	and	J.	A.	Quillfeldt,	
“Differential	 role	 of	 the	 hippocampal	 endocannabinoid	 
system	 in	 the	 memory	 consolidat ion	 and	 retr ieval	
mechanisms,”	Neurobiol. Learn. Mem.,	90,	1-9	(2008).
3.	 R.	 Takahashi,	 F.	 Pamplona,	 and	 M.	 Fernandes,	 “The	
cannabinoid	 antagonist	 SR141716A	 facilitates	 memory	
NEUROPHYSIOLOGY	/	НЕЙРОФИЗИОЛОГИЯ.—2014.—T.	46,	№	2 139
EFFECTS	OF	THE	AGENTS	INFLUENCING	THE	SEROTONERGIC
acquisition	and	consolidation	in	the	mouse	elevated	T-maze,”	
Neurosci. Lett.,	380,	270-275	(2005).
4.	 Y.	Zhang,	K.	Raap,	 F.	Garcia,	 et	 al.,	 “Long-term	 fluoxetine	
produces	 behavioral	 anxiolytic	 effects	 without	 inhibiting	
neuroendocrine	responses	to	conditioned	stress	in	rats,”	Brain 
Res.,	855,	No.	1,	58-66	(2000).
5.	 A.	Mowla,	M.	Mosavinasab,	 and	A.	 Pani,	 “Does	 fluoxetine	
have	any	effect	on	the	cognition	of	patients	with	mild	cognitive	
impairment?	A	double-blind,	placebo-controlled,	clinical	trial,”	
J. Clin. Psychopharmacol.,	27,	No.	1,	67-70	(2007).
6.	 I.	Hervás,	M.	Y.	Vilaró,	L.	Romero,	 et	 al.,	 “Desensitization	
of	5-HT(1A)	autoreceptors	by	a	 low	chronic	 fluoxetine	dose	
effect	 of	 the	 concurrent	 administration	 of	 WAY-100635,”	
Neuropsychopharmacol.	24,	11-20	(2001).
7.	 V.	 D.	 Petkov	 and	 R.	 Kehayov,	 “Effects	 of	 agonists	 and	
antagonists	of	 some	serotonin-receptor	 subtypes	on	memory	
and	their	modulation	by	the	5-HT-uptake	inhibitor	fluoxetine,”	
Acta Physiol. Pharmacol. Bulg.,	20,	Nos.	3/4,	83-90	(1994).
8.	 S.	 Fernández-Pérez,	 D.	 M.	 Pache,	 and	 R.	 D.	 Sewell,	 “Co-
administration	of	fluoxetine	and	WAY100635	improves	short-
term	memory	function,”	Eur. J. Pharmacol.,	522,	Nos.	1/3,	78-
83	(2005).
9.	 C.	J.	Nelson,	W.	P.	Jordan,	and	R.	T.	Bohan,	“Daily	fluoxetine	
administration	 impairs	avoidance	 learning	 in	 the	 rat	without	
altering	 sensory	 thresholds,” Neuropsychopharmacol. Biol. 
Psychiat.,	21,	1043-1057	(1997).
10.	 C.	Rossi,	L.	A.	Pini,	M.	L.	Cupini,	et	al.,	“Endocannabinoids	in	
platelets	of	chronic	migraine	patients	and	medication-overuse	
headache	patients:	relation	with	serotonin	levels,”	Eur. J. Clin. 
Pharmacol.,	64,	1-8	(2008).
11.	 P.	Hasanein	 and	S.	Shahidi,	 “Effects	 of	 combined	 treatment	
with	 vitamins	 C	 and	 E	 on	 passive	 avoidance	 learning	 and	
memory	 in	diabetic	 rats,”	Neurobiol. Learn. Mem.,	93,	 472-
478	(2010).
12.	 P.	Hasanein	 and	 S.	 Shahidi,	 “Preventive	 effect	 of	Teucrium	
polium	on	learning	and	memory	deficits	in	diabetic	rats,”	Med. 
Sci. Monit.,	18,	No.	1,	41-46	(2012).
13.	 S.	 Shahidi,	A.	 Komaki,	M.	Mahmoodi,	 et	 al.,	 “The	 role	 of	
GABAergic	 transmission	 in	 the	dentate	gyrus	on	acquisition,	
consolidation	and	retrieval	of	an	inhibitory	avoidance	learning	
and	memory	task	in	the	rat,”	Brain Res.,	1204,	87-93	(2008).	
14.	 A.	Köfalvi,	R.	T.	J.	Rodrigues,	C.	Ledent,	et	al.,	“Involvement	
of	cannabinoid	receptors	in	the	regulation	of	neurotransmitter	
release	 in	 the	 rodent	 striatum:	 a	 combined	 immunochemical	
and	pharmacological	analysis,”	J.	Neurosci.,	25,		No.	1,	2874-
2884	(2005).
15.	 R.	E.	Hampson,	J.	D.	Simeral,	E.	J.	Kelly,	and	S.	A.	Deadwyler,	
“Tolerance	 to	 the	memory	disruptive	effects	of	cannabinoids	
involves	adaptation	by	hippocampal	neurons,”	Hippocampus,	
13,	No.	5,	543-556	(2003).
16.	 P.	E.	Mallet	and	R.	J.	Beninger,	“The	cannabinoid	CB1	receptor	
antagonist	 SR141716A	 attenuates	 the	 memory	 impairment	
produced	 by	 Δ9-tetrahydrocannabinol	 or	 anandamide,”	
Psychopharmacology,	140,	No.	1,	11-19	(1998).
17.	 M.	Wolff	 and	 J.	 Leander,	 “SR141716A,	 a	 cannabinoid	CB1	
receptor	antagonist	improves	memory	in	a	delayed	radial	maze	
task,”	Eur. J. Pharmacol.,	477,	No.	3,		213-217	(2003).
18.	 M.	Reibaud,	M.	C.	Obinu,	C.	Ledent,	et	al.,	“Enhancement	of	
memory	 in	cannabinoid	CB1	 receptor	knock-out	mice,”	Eur. 
J. Pharmacol.,	379,	R1-R2	(1999).
19.	 P.	 E.	 Rueda-Orozco,	 C.	 J.	 Montes-Rodriguez,	 E.	 Soria-
Gomes,	 et	 al.,	 “Impairment	 of	 endocannabinoids	 activity	 in	
the	 dorsolateral	 striatum	 delays	 extinction	 of	 behavior	 in	 a	
procedural	 memory	 task	 in	 rats,”	Neuropharmacology,	 55,	 
No.	1,	55-62	(2008).
20.	 S.	A.	Varvel,	R.	J.	Hamm,	B.	R.	Martin,	and	A.	H.	Lichtman,	
“Differential	effects	of	delta	9-THC	on	spatial	 reference	and	
working	memory	in	mice,”	Psychopharmacology,	157,	No.	2,	
142-150	(2001).
21.	 N.	M.	White	and	R.	J.	McDonald,	“Multiple	parallel	memory	
systems	 in	 the	brain	of	 the	rat,”	Neurobiol. Learn. Mem.,	77,	
No.	2,	125-184	(2002).	
22.	 L.	 De	 Oliveira	Alvares,	 B.	 P.	 Genro,	 R.	 Vaz	 Breda,	 et	 al.,	
“AM251,	a	selective	antagonist	of	 the	CB1	receptor,	 inhibits	
the	induction	of	long-term	potentiation	and	induces	retrograde	
amnesia	in	rats,”	Brain Res.,	1075,	No.	1,	60-67	(2006).
23.	 M.	 C.	 Carvalho,	 L.	 Albrechet-Souza,	 S.	 Masson,	 and	 
M.	L.	Brandäo,	“Changes	in	the	biogenic	amine	content	of	the	
prefrontal	cortex,	amygdala,	dorsal	hippocampus,	and	nucleus	
accumbens	of	 rats	 submitted	 to	 single	and	 repeated	 sessions	
of	 the	elevated	plus-maze	 test,”	Braz. J. Med. Biol. Res.,	38,	 
No.	12,	1857-1866	(2005).
24.	 J.	M.	Casanovas,	M.	Lésourd,	and	F.	Artigas,	 “The	effect	of	
the	 selective	 5-HT	 1A	 agonists	 alnespirone	 (S-20499)	 and	
8-OH-DPAT	on	extracellular	5-hydroxytryptamine	in	different	
regions	of	rat	brain,”	Dr. J. Pharmacol.,	122,		No.	4,	733-741	
(1997).
25.	 J . 	 H.	 Janssen	 and	 J. 	 S. 	 Andrews,	 “The	 effects	 of	
serotonergic	 drugs	 on	 short-term	 spatial	 memory	 in	 rats,”	 
J. Psychopharmacol.,	8,	No.	3,	157-163	(1994).
26.	 M.	 ElBeltagy,	 S.	 Mustafa,	 J.	 Umka,	 et	 al.,	 “Fluoxetine	
improves	 the	memory	 deficits	 caused	 by	 the	 chemotherapy	
agent	5-fluorouracil,”	Behav. Brain. Res.,	208,	No.	1,	112-117	
(2010).	
27.	 C.	J.	Harmer,	Z.	Bhagwagar,	P.	J.	Cowen,	and	G.	M.	Goodwin,	
“Acute	 administration	 of	 citalopram	 facilitates	 memory	
consolidation	 in	 healthy	 volunteers,”	Psychopharmacology,	
163,	No.	1,	106-110	(2002).
28.	 J.	D.	 Joss,	R.	M.	Burton,	and	C.	A.	Keller,	“Memory	 loss	 in	
a	 patient	 treated	with	 fluoxetine,”	Ann.	Pharmacother.,	37,	 
No.	12,	1800-1803	(2003).
29.	 N.	Majlessi	and	N.	Naghdi,	“Impaired	spatial	 learning	 in	 the	
Morris	water	maze	induced	by	serotonin	reuptake	inhibitors	in	
rats,”	Behav. Pharmacol.,	13,	No.	3,	237-242	(2002).
30.	 M.	Kodama,	T.	Fujioka,	and	R.	S.	Duman,	“Chronic	olanzapine	
or	 fluoxetine	 administration	 increases	 cell	 proliferation	
in	 hippocampus	 and	 prefrontal	 cortex	 of	 adult	 rat,”	 Biol. 
Psychiat.,	56,	No.	8,	570-580	(2004).
31.	 T.	 Lau	 and	 P.	 Schloss,	 “The	 cannabinoid	 CB1	 receptor	 is	
expressed	 on	 serotonergic	 and	 dopaminergic	 neurons,”	Eur. 
J. Pharmacol.,	578,	Nos.	2/3,	137-141	(2008).
32.	 M.	 N.	 Hill,	 W.	 S.	 Ho,	 C.	 J.	 Hillard,	 and	 B.	 B.	 Gorzalka,	
“Differential	 effects	 of	 the	 antidepressants	 tranylcypromine	
and	 fluoxetine	 on	 limbic	 cannabinoid	 receptor	 binding	 and	
endocannabinoid	contents,”	J.	Neural Transm.,	115,	No.	12,	
1673-1679	(2008).
33.	 J.	Chen,	W.	Paredes,	J.	H.	Lowinson,	and	E.	L.	Gardner,	“Delta	
9-tetrahydrocannabinol	enhances	presynaptic	dopamine	efflux	
in	medial	prefrontal	cortex,”	Eur. J. Pharmacol.,	190,	Nos.	1/2,	
259-262	(1990).
34.	 M.	Matsumoto,	M.	Yoshioka,	H.	Togashi,	 et	al.,	 “Functional	
regulation	 by	 dopamine	 receptors	 of	 serotonin	 release	 from	
the	 rat	 hippocampus:	 in vivo	 microdialysis	 study,”	Naunyn 
Schmiedebergs Arch.	Pharmacol.,	353,	No.	6,	621-629	(1996).
NEUROPHYSIOLOGY	/	НЕЙРОФИЗИОЛОГИЯ.—2014.—T.	46,	№	2140
N.	REZAPOOR,	S.	SHAHIDI,	and	A.	KOMAKI
35.	 H.	K.	Kia,	M.	J.	Brisorgueil,	M.	Hamon,	et	al.,	“Ultrastructural	
localization	 of	 5-hydroxytryptamine1A	 receptors	 in	 the	 rat	
brain,”	J. Neurosci. Res.,	46,	No.	6,	697-708	(1996).	
36.	 E.	Gould,	A.	Beylin,	 P.	Tanapat,	 et	 al.,	 “Learning	 enhances	
adult	 neurogenesis	 in	 the	 hippocampal	 formation,”	 Nat. 
Neurosci.,	2,	260-265	(1999).
37.	 D.	 Panikashvili,	 C.	 Simeonidou,	 S.	 Ben-Shabat,	 et	 al.,	 “An	
endogenous	cannabinoid	(2-AG)	is	neuroprotective	after	brain	
injury,”	Nature,	413,	No.	6855,	527-531	(2001).
